Program Information

Friday, December 9, 2022

CME Symposium
7:00 AM – 10:00 AM CT

Ernest N. Morial Convention Center
Great Hall A/D
900 Convention Center Blvd
New Orleans, LA 70130


6:30 AM - 7:00 AM
Registration and Coffee/Tea Service
7:00 AM - 7:05 AM
LLS Overview
Lee Greenberger, PhD
7:05 AM - 7:10 AM
Helen E. Heslop, MD, DSc (Hon) (Chair)
7:10 AM - 7:40 AM
Bispecific Antibodies Latch Onto Advances
Saad Z. Usmani, MD, MBA, FACP
7:40 AM - 8:10 AM
Approaches Beyond Classic CAR T-Cells
Helen E. Heslop, MD, DSc (Hon)
8:10 AM - 8:40 AM
PROTACs: A Paradigm Shift in Drug Discovery
Katherine Donovan, PhD
8:40 AM - 9:10 AM
Novel ADC Target Hunting in Pediatric AML
Soheil Meshinchi, MD, PhD
9:10 AM - 9:40 AM
Cell-Free DNA Potential in Guiding Therapies
Mark Roschewski, MD
9:40 AM - 10:00 AM
Panel Discussion/Q&A Session
All Faculty


Helen E. Heslop, MD, DSc (Hon) (Chair)
Professor, Departments of Medicine and Pediatrics
Director, Center for Cell and Gene Therapy
Dan L. Duncan Chair
Interim Director, Dan L. Duncan Comprehensive Cancer Center
Baylor College of Medicine
Houston, TX

Katherine Donovan, PhD
Lead Scientist, Department of Cancer Biology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA

Soheil Meshinchi, MD, PhD
Full Member
Fred Hutchinson Cancer Center
Professor, Pediatrics
University of Washington
Seattle, WA

Mark Roschewski, MD
Clinical Director, Lymphoid Malignancies Branch
Center for Cancer Research
National Cancer Institute, NIH
Bethesda, MD

Saad Z. Usmani, MD, MBA, FACP
Chief, Myeloma Service
Memorial Sloan Kettering Cancer Center
New York, NY

Hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.

Upon completion of this activity, participants should be better able to:

  • Analyze available data on bispecific antibodies for the treatment of multiple myeloma
  • Identify potential T-cell immunotherapeutic strategies for the treatment of lymphomas and other hematologic malignancies
  • Describe emerging proteolysis targeting chimeras (PROTACs) under investigation for the treatment of hematologic malignancies
  • Assess key data sets and ongoing clinical trials investigating antibody-drug conjugates for the treatment of acute myeloid leukemia (AML)
  • Examine the potential utility of circulating tumor DNA for risk prediction and individualizing therapy for diffuse large B-cell lymphoma (DLBCL)


Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by RMEI Medical Education, LLC and The Leukemia & Lymphoma Society. RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
RMEI Medical Education, LLC designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI will disclose to learners the presence or absence of relevant financial relationships for all persons in control of content before the learner engages in the education.

There is no fee for this educational activity.

Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc).
Please contact RMEI prior to the live event at

For information on leukemia, lymphoma, or myeloma, contact an LLS Information Specialist at (800) 955-4572 or, or visit

Facebook Twitter YouTube